(Thyroid Cancer) Is Vandetanib Monotherapy Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- July 13, 2020
- Read time: 2 minutes
On June 25, 2020, Javier Cortés published in the medical journal Journal of Clinical Oncology the "Efficacy and safety validation results from the ZETA Phase 3 clinical trial subgroup analysis of VEGFR/EGFR kinase inhibitor vandetanib in progressive and symptomatic medullary thyroid cancer patients."
The ZETA Phase 3 clinical trial randomized progressive/symptomatic medullary thyroid cancer patients (N=331) in a 2:1 ratio into the following two groups, with the primary endpoint being progression-free survival and secondary endpoints being objective response rate and overall survival.
- Vandetanib group (once-daily vandetanib 300 mg, N=231).
- Placebo group (N=100).
The trial included four patient categories: 1. Progressive and symptomatic; 2. Symptomatic only; 3. Progressive only; 4. Neither progressive nor symptomatic. The subgroup analysis target was progressive and symptomatic patients (N=184).
Subgroup analysis results: the primary endpoint median progression-free survival for progressive and symptomatic medullary thyroid cancer patients was: vandetanib group 21.43 months / placebo group 8.40 months.
Regarding safety, the adverse events that occurred in the vandetanib group were consistent with those seen in other clinical trials. The most commonly observed adverse events included digestive system issues and skin problems.
Based on the ZETA clinical trial subgroup analysis results, Michael C. Kreissl concluded: In progressive and symptomatic medullary thyroid cancer patients, VEGFR/EGFR kinase inhibitor vandetanib improved progression-free survival with clinically significant effect.
[Important Note] Medical Supporter's translations of overseas clinical trial data and pharmaceutical information are not intended to encourage participation in clinical trials or use of new drugs. The translated information is for reference only and not intended as medication guidelines. Please discuss with healthcare professionals and refer to the original text below the article for accurate information.
Source: Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial (J Clin Oncol. 2020 Jun 25;JCO1902790. doi: 10.1200/JCO.19.02790.)
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4